黄斑变性治疗市场：按类型、阶段、管理途径、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2028

黄斑变性是一种眼部疾病，会影响黄斑（眼睛后部视网膜的感光中心）并降低中心视力。它通常是由异常血管将液体或血液渗入黄斑引起的。年龄相关性黄斑变性有两种类型：干性和湿性。没有治愈方法，但黄斑变性 (AMD) 治疗可以减缓疾病的进展并防止严重的视力丧失。然而，治疗取决于疾病的阶段和类型。干型往往比湿型进展得更慢，目前还没有批准的治疗方法或治疗方法。干型更常见，通常进展缓慢（多年）。然而，治疗取决于 AMD 的类型。

市场动态。

视网膜疾病患病率的上升、老年人口的增加、对安全有效治疗的需求上升、临床试验的增加等预计将成为推动全球黄斑变性治疗市场增长的主要因素。例如，根据美国疾病控制和预防中心 (CDC) 的数据，年龄相关性黄斑变性是全球失明的主要原因，也是 65 岁及以上美国人视力丧失和失明的主要原因。到 2050 年，预计从 4800 万增加到 8800 万。

2021 年 9 月，美国食品药品监督管理局 (Food and Drug Administration) (FDA) 宣布了首个用于新血管形成的 Lucentis（雷珠单抗注射液）生物仿製药，这是导致 65 岁及以上美国人视力丧失和失明的主要原因。治疗多种眼部疾病，包括老年性黄斑变性（nAMD）。

本研究的主要特点

• 本报告对全球黄斑变性治疗市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2028 年）的市场规模和復合年增长率 (CAGR %)。我是这里。
• 它还揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
• 它还提供有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争策略等方面的重要见解。
• 它根据以下参数描述了全球黄斑变性治疗市场的主要参与者，包括公司亮点、产品组合、关键亮点、绩效和策略。
• 本研究涵盖的主要公司包括 Bayer AG、REGENXBIO Inc.、Panoptica、Pfizer Inc.、F. Hoffmann-La Roche Ltd.、Regeneron Pharmaceutical Inc.、Novartis AG、Aerie Pharmaceutical Inc. 和 Bausch健康公司
• 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。.
• 全球黄斑变性治疗市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
• 利益相关者可以通过用于分析全球黄斑变性治疗市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场快照：按类型
  • 市场概况：按疾病阶段
  • 按管理途径划分的市场概况
  • 市场快照：按销售渠道
  • 市场概况：按地区划分
• 连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 全球视网膜疾病负担不断上升
  • 对黄斑变性的认识不足
  • 对安全有效治疗的需求不断增加
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/批准
• PEST 分析
• PORTER 分析
• 併购方案

第 4 章黄斑变性治疗市场：冠状病毒 (COVID-19) 大流行的影响

• COVID-19 的流行病学
• 供应方和需求方分析
• 经济影响

第 5 章黄斑变性治疗市场：按类型，2017-2028 年

• 干性老年性黄斑变性
• 湿性老年性黄斑变性

第 6 章黄斑变性治疗市场：分阶段，2017-2028

• 早期 AMD
• 中期 AMD
• 晚期 AMD

第 7 章黄斑变性治疗市场：按管理途径，2017-2028 年

• 静脉给药途径
• 玻璃体内给药途径

第 8 章黄斑变性治疗市场：按分销渠道，2017-2028

• 门诊手术中心
• 医院
• 其他销售渠道

第 9 章黄斑变性治疗市场：2017-2028 年各地区

• 北美
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲
• 世界其他地区

第 10 章竞争格局

• Bayer AG, REGENXBIO Inc.
• Aerie Pharmaceutical Inc.
• Panoptica
• Pfizer Inc.
• Hoffmann-La Roche Ltd.
• Regeneron Pharmaceutical Inc.
• Novartis AG
• Bausch Health Companies Inc.

第 11 章章节

• 调查方法介绍
• 关于出版商

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics:

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study:

• This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Detailed Segmentation:

• Global Macular Degeneration Treatment Market, By Type:
  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration
• Global Macular Degeneration Treatment Market, By Stage of Disease:
  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD
• Global Macular Degeneration Treatment Market, By Route of Administration:
  • Intravenous Route
  • Intravitreal Route
• Global Macular Degeneration Treatment Market, By Sales Channel:
  • Ambulatory Surgical Centres
  • Hospitals
  • Other Sales Channels
• Global Macular Degeneration Treatment Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Stage od Disease
  • Market Snapshot, By By Route of Administration
  • Market Snapshot, By Sales Channel
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing burden of retinal disorders worldwide
  • Lack of awareness regarding macular degeneration
  • Increasing demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Macular Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Macular Degeneration Treatment Market, By Type, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Dry Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Wet Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Macular Degeneration Treatment Market, By Stage of Disease, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Early-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Intermediate AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Late-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Macular Degeneration Treatment Market, By Route of Administration, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Intravenous Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Intravitreal Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

8. Macular Degeneration Treatment Market, By Sales Channel, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Ambulatory Surgical Centres
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Sales Channels
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

9. Macular Degeneration Treatment Market, By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

10. Competitive Landscape

• Bayer AG, REGENXBIO Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aerie Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panoptica
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us